

## Symposium: Liver Fibrosis, Cirrhosis and HCC: Recent Advances

內容簡述：Although MAFLD (Metabolic dysfunction-associated fatty liver disease) is a growing disease contributing to cirrhosis and HCC in the era of post-HBV global vaccination and anti-viral therapies for HBV and HCV. The image diagnosis remains challenge in the stage of cirrhosis and HCC development. US-guide ablation including RFA, MWA and proton beam therapy have also been developed for early stage of HCC. This symposium will briefly introduce the advances.

時間 Time	演講題目 Topic	演講者 Speaker
Moderator: 陳冠仰 Kuan-Yang Chen 臺北市立聯合醫院陽明院區		
14:00-14:05	Opening Remarks	陳冠仰 Kuan-Yang Chen 臺北市立聯合醫院陽明院區
14:05-14:25 GI-S06	MAFLD, Fibrosis and Cirrhosis	林志陵 Chih-Lin Lin 臺北市立聯合醫院仁愛院區
14:25-14:45 GI-S07	AI and Fibro-scan in MAFLD	戴達英 Dar-In Tai 林口長庚醫院
14:45-15:05 GI-S08	HCC in MAFLD, Image Diagnosis	吳志宏 Chih-Horng Wu 台大醫院
15:05-15:20	Discussion	All speakers
15:20-15:40	Coffee Break	
Moderator: 林錫銘 Shi-Ming Lin 林口長庚醫院胃腸肝膽科系		
15:40-16:00 GI-S09	RFA in HCC: Single or Multi-electrodes	高偉育 Wei-Yu Kao 臺北醫學大學附設醫院
16:00-16:20 GI-S10	MWA in HCC	劉高郎 Kao-Lang Liu 台大醫院
16:20-16:40 GI-S11	Proton-beam Therapy in HCC	黃炳勝 Bing-Shen Huang 林口長庚醫院
16:40-16:55	Discussion	All speakers
16:55-17:00	Closing Remarks	林錫銘 Shi-Ming Lin 林口長庚醫院胃腸肝膽科系